Barclays
AEON icon

Barclays’s AEON Biopharma AEON Stock Holding History

Barclays’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-21
Closed -$17 – 5204
2025
Q3 		$17 Buy
+21
New +$16 ﹤0.01% 5368
2023
Q3 		– Sell
-3
Closed -$1.37K – 4581
2023
Q2 		$1.37K Hold
3
– – ﹤0.01% 4343
2023
Q1 		$1.97K Sell
3
-283
-99% -$205K ﹤0.01% 4892
2022
Q4 		$207K Hold
286
– – ﹤0.01% 3822
2022
Q3 		$203K Buy
+286
New +$203K ﹤0.01% 3195

Other funds holding AEON

DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Barclays's AEON Position: Q4 2025 in Review

Barclays sold out of AEON Biopharma (AEON) in Q4 2025, closing a stake of 21 shares — an estimated $17 sold.

Barclays first reported a position in AEON in Q3 2022 and held it in 5 quarters. The position peaked at $207K in Q4 2022. 22 funds tracked by Wall St. Rank hold AEON as of Q4 2025.

  • Barclays reported no remaining AEON Biopharma position as of Q4 2025 after selling out during the quarter.
  • Barclays sold 21 AEON Biopharma shares in Q4 2025, an estimated $17.
  • Barclays first reported a position in AEON Biopharma in Q3 2022 and held it in 5 quarters.
  • Barclays's AEON Biopharma position peaked at $207K in Q4 2022.
  • 22 funds tracked by Wall St. Rank held AEON Biopharma as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.